Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model
Hepatitis-B vaccine (HBVv) can prevent HBV-infection and associated liver diseases. However, concerns regarding its safety, particularly among patients with autoimmune diseases (i.e. SLE) were raised. Moreover, the aluminum adjuvant in HBVv was related to immune mediated adverse events. Therefore, w...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2014
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22257
- Acceso en línea:
- https://doi.org/10.1016/j.jaut.2014.06.006
https://repository.urosario.edu.co/handle/10336/22257
- Palabra clave:
- Aluminum hydroxide
Double stranded dna antibody
Hepatitis b surface antigen
Immunological adjuvant
Phosphate buffered saline
Recombinant hepatitis b vaccine
Antinuclear antibody
Hepatitis b vaccine
Animal experiment
Animal model
Animal tissue
Antibody titer
Anxiety
Article
Autoimmune disease
Blood cell count
Brain histology
Brain region
Cell lineage
Cognition
Controlled study
Disease exacerbation
Drug safety
Erythrocyte
Female
Forced swim test
Gliosis
Immunization
Kidney disease
Lupus like syndrome
Memory disorder
Microglia
Mouse
Nonhuman
Novel object recognition test
Proteinuria
Staircase test
Systemic lupus erythematosus
Y-maze test
Animal
Brain
Disease model
Drug effects
Immunology
Lupus erythematosus nephritis
Pathology
Pathophysiology
Animals
Brain
Cognition
Female
Hepatitis b vaccines
Lupus nephritis
Mice
Proteinuria
Autoimmune/autoinflammatory syndrome induced by adjuvant (asia)
Autoimmunity
Hepatitis b vaccine
Neuro-cognitive tests
Sle
Vaccination
animal
antinuclear
Antibodies
Disease models
- Rights
- License
- Abierto (Texto Completo)
Summary: | Hepatitis-B vaccine (HBVv) can prevent HBV-infection and associated liver diseases. However, concerns regarding its safety, particularly among patients with autoimmune diseases (i.e. SLE) were raised. Moreover, the aluminum adjuvant in HBVv was related to immune mediated adverse events. Therefore, we examined the effects of immunization with HBVv or alum on SLE-like disease in a murine model.NZBWF1 mice were immunized with HBVv (Engerix), or aluminum hydroxide (alum) or phosphate buffered saline (PBS) at 8 and 12 weeks of age. Mice were followed for weight, autoantibodies titers, blood counts, proteinuria, kidney histology, neurocognitive functions (novel object recognition, staircase, Y-maze and the forced swimming tests) and brain histology.Immunization with HBVv induced acceleration of kidney disease manifested by high anti-dsDNA antibodies (. p less than 0.01), early onset of proteinuria (. p less than 0.05), histological damage and deposition of HBs antigen in the kidney. Mice immunized with HBVv and/or alum had decreased cells counts mainly of the red cell lineage (. p less than 0.001), memory deficits (. p less than 0.01), and increased activated microglia in different areas of the brain compare with mice immunized with PBS. Anxiety-like behavior was more pronounced among mice immunized with alum.In conclusion, herein we report that immunization with the HBVv aggravated kidney disease in an animal model of SLE. Immunization with either HBVv or alum affected blood counts, neurocognitive functions and brain gliosis. Our data support the concept that different component of vaccines may be linked with immune and autoimmune mediated adverse events. © 2014 Elsevier Ltd. |
---|